

## UROPLASTY, INC. ANNOUNCES DISTRIBUTION AGREEMENT FOR EASYCONT P/Q<sup>TM</sup> INCONTINENCE DIAGNOSTIC DEVICE

Minneapolis, MN, December 4, 2006 -- Uroplasty, Inc. (AMEX: [UPI](#)) announced an exclusive distribution agreement with S.I.E.M srl of Milan, Italy to distribute the EasyCont P/Q<sup>TM</sup> urodynamic diagnostic device. Under the agreement, Uroplasty has exclusive distribution rights in all countries except Italy. The company plans to begin marketing the EasyCont device in certain western European countries and the United Kingdom in early 2007.

With about a decade of experience in urodynamics, S.I.E.M developed the EasyCont, which includes a patented Q-Tip device, for the diagnosis of urinary incontinence. This self-contained, portable and compact device enables surgeons to perform fast, repeatable and accurate diagnostic tests in the surgeon's office, outpatient clinic or hospital daycase unit.

David B. Kaysen, President and CEO of Uroplasty said, "The EasyCont is a significant addition to our portfolio of office-based solutions for voiding dysfunctions. We expect it will enable gynecologists, urogynecologists and urologists to determine the optimal treatment for patients suffering from urinary incontinence. We anticipate this diagnostic device will complement the use of other Uroplasty products such as our Macroplastique® bulking agent, indicated for the treatment of stress urinary incontinence primarily due to intrinsic sphincter deficiency, the I-Stop<sup>TM</sup> Sling, indicated for the treatment of stress urinary incontinence due to bladder hypermobility or the Urgent® PC, indicated for the treatment of symptoms of over active bladder."

\*\*\*\*\*

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. Uroplasty's minimally invasive products treat urinary incontinence and overactive bladder symptoms. We believe that our company is uniquely positioned because we offer a broad and diverse set of products to address the various preferences of doctors and patients, as well as the quality of life issues presented by voiding dysfunctions.

Uroplasty's other products for the treatment of incontinence and overactive bladder symptoms include:

- Macroplastique®, a minimally invasive, implantable soft tissue bulking agent for the treatment of stress urinary incontinence. When Macroplastique is injected into tissue around the urethra, it stabilizes and "bulks" tissues close to the urethra, thereby providing the surrounding muscles with increased capability to control the release of urine.
- I-Stop<sup>TM</sup>, a minimally invasive biocompatible, polypropylene, tension-free sling for the treatment of female urinary incontinence. The I-Stop sling can correct stress urinary incontinence by providing tension-free hammock-type support for the urethra to prevent its downward movement and the associated leakage of urine.
- The Urgent® PC neuromodulation system, a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. This product uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. This press release contains forward-looking statements, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words "aim," "believe," "expect," "anticipate," "intend," "estimate" and other expressions, which indicate future events and trends, identify forward-looking

statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price. We cannot assure that we can profitably market the EasyCont P/Q™ urodynamic diagnostic device.

FOR FURTHER INFORMATION: visit Uroplasty's web page at [www.uroplasty.com](http://www.uroplasty.com) or contact Mr. Kaysen.

UROPLASTY, INC.

David B. Kaysen, President / CEO

5420 Feltl Road

Minnetonka, Minnesota 55343

Tel: 952.426.6140 Fax: 952.426.6199

E-mail: [dave.kaysen@uroplasty.com](mailto:dave.kaysen@uroplasty.com)